ID   H2AY_HUMAN              Reviewed;         372 AA.
AC   O75367; O75377; Q503A8; Q7Z5E3; Q96D41; Q9H8P3; Q9UP96;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   22-JUL-2015, entry version 159.
DE   RecName: Full=Core histone macro-H2A.1;
DE            Short=Histone macroH2A1;
DE            Short=mH2A1;
DE   AltName: Full=Histone H2A.y;
DE            Short=H2A/y;
DE   AltName: Full=Medulloblastoma antigen MU-MB-50.205;
GN   Name=H2AFY; Synonyms=MACROH2A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9714746; DOI=10.1016/S0167-4781(98)00098-0;
RA   Lee Y., Hong M., Kim J.W., Hong Y.M., Choe Y.-K., Chang S.Y.,
RA   Lee K.S., Choe I.S.;
RT   "Isolation of cDNA clones encoding human histone macroH2A1 subtypes.";
RL   Biochim. Biophys. Acta 1399:73-77(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=9653160; DOI=10.1073/pnas.95.14.8175;
RA   Mao M., Fu G., Wu J.-S., Zhang Q.-H., Zhou J., Kan L.-X., Huang Q.-H.,
RA   He K.-L., Gu B.-W., Han Z.-G., Shen Y., Gu J., Yu Y.-P., Xu S.-H.,
RA   Wang Y.-X., Chen S.-J., Chen Z.;
RT   "Identification of genes expressed in human CD34(+) hematopoietic
RT   stem/progenitor cells by expressed sequence tags and efficient full-
RT   length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8175-8180(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Ovary;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Bone marrow, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-372 (ISOFORM 3).
RC   TISSUE=Medulloblastoma;
RX   PubMed=12800201; DOI=10.1002/ijc.11208;
RA   Behrends U., Schneider I., Roessler S., Frauenknecht H., Golbeck A.,
RA   Lechner B., Eigenstetter G., Zobywalski C., Mueller-Weihrich S.,
RA   Graubner U., Schmid I., Sackerer D., Spaeth M., Goetz C., Prantl F.,
RA   Asmuss H.-P., Bise K., Mautner J.;
RT   "Novel tumor antigens identified by autologous antibody screening of
RT   childhood medulloblastoma cDNA libraries.";
RL   Int. J. Cancer 106:244-251(2003).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9634239; DOI=10.1038/31275;
RA   Costanzi C., Pehrson J.R.;
RT   "Histone macroH2A1 is concentrated in the inactive X chromosome of
RT   female mammals.";
RL   Nature 393:599-601(1998).
RN   [8]
RP   FUNCTION.
RX   PubMed=12718888; DOI=10.1016/S1097-2765(03)00100-X;
RA   Angelov D., Molla A., Perche P.-Y., Hans F., Cote J., Khochbin S.,
RA   Bouvet P., Dimitrov S.;
RT   "The histone variant macroH2A interferes with transcription factor
RT   binding and SWI/SNF nucleosome remodeling.";
RL   Mol. Cell 11:1033-1041(2003).
RN   [9]
RP   UBIQUITINATION AT LYS-116 AND LYS-117, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=16129414; DOI=10.1016/j.bbrc.2005.08.046;
RA   Ogawa Y., Ono T., Wakata Y., Okawa K., Tagami H., Shibahara K.;
RT   "Histone variant macroH2A1.2 is mono-ubiquitinated at its histone
RT   domain.";
RL   Biochem. Biophys. Res. Commun. 336:204-209(2005).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15621527; DOI=10.1016/j.devcel.2004.10.019;
RA   Zhang R., Poustovoitov M.V., Ye X., Santos H.A., Chen W.,
RA   Daganzo S.M., Erzberger J.P., Serebriiskii I.G., Canutescu A.A.,
RA   Dunbrack R.L., Pehrson J.R., Berger J.M., Kaufman P.D., Adams P.D.;
RT   "Formation of MacroH2A-containing senescence-associated
RT   heterochromatin foci and senescence driven by ASF1a and HIRA.";
RL   Dev. Cell 8:19-30(2005).
RN   [11]
RP   BINDING TO ADP-RIBOSE (ISOFORM 1).
RX   PubMed=15902274; DOI=10.1038/sj.emboj.7600664;
RA   Karras G.I., Kustatscher G., Buhecha H.R., Allen M.D., Pugieux C.,
RA   Sait F., Bycroft M., Ladurner A.G.;
RT   "The macro domain is an ADP-ribose binding module.";
RL   EMBO J. 24:1911-1920(2005).
RN   [12]
RP   IDENTIFICATION IN A COMPLEX WITH CULLIN3 AND SPOP, UBIQUITINATION,
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15897469; DOI=10.1073/pnas.0408918102;
RA   Hernandez-Munoz I., Lund A.H., van der Stoop P., Boutsma E.,
RA   Muijrers I., Verhoeven E., Nusinow D.A., Panning B., Marahrens Y.,
RA   van Lohuizen M.;
RT   "Stable X chromosome inactivation involves the PRC1 Polycomb complex
RT   and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3
RT   ligase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7635-7640(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-129 AND THR-178, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   FUNCTION.
RX   PubMed=16428466; DOI=10.1128/MCB.26.3.1156-1164.2006;
RA   Doyen C.-M., An W., Angelov D., Bondarenko V., Mietton F.,
RA   Studitsky V.M., Hamiche A., Roeder R.G., Bouvet P., Dimitrov S.;
RT   "Mechanism of polymerase II transcription repression by the histone
RT   variant macroH2A.";
RL   Mol. Cell. Biol. 26:1156-1164(2006).
RN   [15]
RP   METHYLATION AT LYS-18 AND LYS-123, PHOSPHORYLATION AT THR-129, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16210244; DOI=10.1074/mcp.M500285-MCP200;
RA   Chu F., Nusinow D.A., Chalkley R.J., Plath K., Panning B.,
RA   Burlingame A.L.;
RT   "Mapping post-translational modifications of the histone variant
RT   MacroH2A1 using tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 5:194-203(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-129, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-170 AND THR-178, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-129; SER-170; SER-173
RP   AND THR-178, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-129 AND THR-178, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-129 AND SER-170, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 1-120 IN COMPLEX WITH THE
RP   NUCLEOSOME CORE PARTICLE, AND FUNCTION.
RX   PubMed=16107708; DOI=10.1128/MCB.25.17.7616-7624.2005;
RA   Chakravarthy S., Gundimella S.K., Caron C., Perche P.-Y.,
RA   Pehrson J.R., Khochbin S., Luger K.;
RT   "Structural characterization of the histone variant macroH2A.";
RL   Mol. Cell. Biol. 25:7616-7624(2005).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.54 ANGSTROMS) OF 162-372 (ISOFORM 1), X-RAY
RP   CRYSTALLOGRAPHY (2.92 ANGSTROMS) OF 161-372 (ISOFORM 2), AND BINDING
RP   TO ADP-RIBOSE AND O-ACETYL-ADP-RIBOSE (ISOFORM 1).
RX   PubMed=15965484; DOI=10.1038/nsmb956;
RA   Kustatscher G., Hothorn M., Pugieux C., Scheffzek K., Ladurner A.G.;
RT   "Splicing regulates NAD metabolite binding to histone macroH2A.";
RL   Nat. Struct. Mol. Biol. 12:624-625(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.43 ANGSTROMS) OF 172-186 IN COMPLEXES WITH
RP   SPOP, SUBUNIT, AND UBIQUITINATION.
RX   PubMed=19818708; DOI=10.1016/j.molcel.2009.09.022;
RA   Zhuang M., Calabrese M.F., Liu J., Waddell M.B., Nourse A., Hammel M.,
RA   Miller D.J., Walden H., Duda D.M., Seyedin S.N., Hoggard T.,
RA   Harper J.W., White K.P., Schulman B.A.;
RT   "Structures of SPOP-substrate complexes: insights into molecular
RT   architectures of BTB-Cul3 ubiquitin ligases.";
RL   Mol. Cell 36:39-50(2009).
CC   -!- FUNCTION: Variant histone H2A which replaces conventional H2A in a
CC       subset of nucleosomes where it represses transcription.
CC       Nucleosomes wrap and compact DNA into chromatin, limiting DNA
CC       accessibility to the cellular machineries which require DNA as a
CC       template. Histones thereby play a central role in transcription
CC       regulation, DNA repair, DNA replication and chromosomal stability.
CC       DNA accessibility is regulated via a complex set of post-
CC       translational modifications of histones, also called histone code,
CC       and nucleosome remodeling. Involved in stable X chromosome
CC       inactivation. Inhibits the binding of transcription factors and
CC       interferes with the activity of remodeling SWI/SNF complexes.
CC       Inhibits histone acetylation by EP300 and recruits class I HDACs,
CC       which induces a hypoacetylated state of chromatin. In addition,
CC       isoform 1, but not isoform 2, binds ADP-ribose and O-acetyl-ADP-
CC       ribose, and may be involved in ADP-ribose-mediated chromatin
CC       modulation. {ECO:0000269|PubMed:12718888,
CC       ECO:0000269|PubMed:15621527, ECO:0000269|PubMed:15897469,
CC       ECO:0000269|PubMed:16107708, ECO:0000269|PubMed:16428466}.
CC   -!- SUBUNIT: The nucleosome is a histone octamer containing two
CC       molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4
CC       heterotetramer and two H2A-H2B heterodimers. Interacts with HDAC1
CC       and HDAC2 (By similarity). Interacts with SPOP. Part of a complex
CC       consisting of H2AFY, CUL3 and SPOP. {ECO:0000250,
CC       ECO:0000269|PubMed:15897469, ECO:0000269|PubMed:16107708,
CC       ECO:0000269|PubMed:19818708}.
CC   -!- INTERACTION:
CC       P04626:ERBB2; NbExp=6; IntAct=EBI-2868511, EBI-641062;
CC       A1L162:ERICH2; NbExp=3; IntAct=EBI-2868511, EBI-2682520;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome. Note=Enriched in
CC       inactive X chromosome chromatin and in senescence-associated
CC       heterochromatin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2;
CC         IsoId=O75367-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=O75367-2; Sequence=VSP_002056;
CC         Note=Specifically binds ADP-ribose and O-acetyl-ADP-ribose.
CC         Important residues for binding are Asp-203, Gly-224, Gly-314 and
CC         Phe-348.;
CC       Name=3;
CC         IsoId=O75367-3; Sequence=VSP_038379;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9714746}.
CC   -!- PTM: Monoubiquitinated at either Lys-116 or Lys-117. May also be
CC       polyubiquitinated. Ubiquitination is mediated by the CUL3/SPOP E3
CC       complex and does not promote proteasomal degradation. Instead, it
CC       is required for enrichment in inactive X chromosome chromatin.
CC       {ECO:0000269|PubMed:15897469, ECO:0000269|PubMed:16129414,
CC       ECO:0000269|PubMed:19818708}.
CC   -!- MISCELLANEOUS: The number of individuals with antibodies against
CC       this antigen is 2-fold higher in pediatric patients with cancer
CC       compared to healthy controls.
CC   -!- SIMILARITY: Contains 1 histone H2A domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 Macro domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00490}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF041483; AAC33433.1; -; mRNA.
DR   EMBL; AF044286; AAC33434.1; -; mRNA.
DR   EMBL; AF054174; AAC39908.1; -; mRNA.
DR   EMBL; AK023409; BAB14565.1; -; mRNA.
DR   EMBL; AC026691; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC013331; AAH13331.1; -; mRNA.
DR   EMBL; BC095406; AAH95406.1; -; mRNA.
DR   EMBL; AY134746; AAN08620.1; -; mRNA.
DR   CCDS; CCDS4183.1; -. [O75367-3]
DR   CCDS; CCDS4184.1; -. [O75367-2]
DR   CCDS; CCDS4185.1; -. [O75367-1]
DR   RefSeq; NP_001035248.1; NM_001040158.1. [O75367-3]
DR   RefSeq; NP_004884.1; NM_004893.2. [O75367-3]
DR   RefSeq; NP_613075.1; NM_138609.2. [O75367-2]
DR   RefSeq; NP_613258.2; NM_138610.2. [O75367-1]
DR   RefSeq; XP_011542030.1; XM_011543728.1. [O75367-1]
DR   RefSeq; XP_011542031.1; XM_011543729.1. [O75367-1]
DR   RefSeq; XP_011542032.1; XM_011543730.1. [O75367-3]
DR   UniGene; Hs.420272; -.
DR   UniGene; Hs.599225; -.
DR   PDB; 1U35; X-ray; 3.00 A; C/G=1-120.
DR   PDB; 1ZR3; X-ray; 1.66 A; A/B/C/D=162-372.
DR   PDB; 1ZR5; X-ray; 2.92 A; A/B=161-372.
DR   PDB; 2F8N; X-ray; 2.90 A; G=1-120.
DR   PDB; 2FXK; X-ray; 2.54 A; A/B=162-372.
DR   PDB; 3HQH; X-ray; 2.30 A; M=167-181.
DR   PDB; 3HSV; X-ray; 1.43 A; M=172-186.
DR   PDB; 3IID; X-ray; 1.90 A; A=162-372.
DR   PDB; 3IIF; X-ray; 2.10 A; A/B/C=162-372.
DR   PDB; 3IVB; X-ray; 1.75 A; M=167-181.
DR   PDBsum; 1U35; -.
DR   PDBsum; 1ZR3; -.
DR   PDBsum; 1ZR5; -.
DR   PDBsum; 2F8N; -.
DR   PDBsum; 2FXK; -.
DR   PDBsum; 3HQH; -.
DR   PDBsum; 3HSV; -.
DR   PDBsum; 3IID; -.
DR   PDBsum; 3IIF; -.
DR   PDBsum; 3IVB; -.
DR   ProteinModelPortal; O75367; -.
DR   SMR; O75367; 10-117, 181-369.
DR   BioGrid; 114927; 47.
DR   DIP; DIP-44283N; -.
DR   IntAct; O75367; 8.
DR   MINT; MINT-2866965; -.
DR   STRING; 9606.ENSP00000423563; -.
DR   PhosphoSite; O75367; -.
DR   BioMuta; H2AFY; -.
DR   SWISS-2DPAGE; O75367; -.
DR   MaxQB; O75367; -.
DR   PaxDb; O75367; -.
DR   PRIDE; O75367; -.
DR   DNASU; 9555; -.
DR   Ensembl; ENST00000304332; ENSP00000302572; ENSG00000113648. [O75367-3]
DR   Ensembl; ENST00000312469; ENSP00000310169; ENSG00000113648. [O75367-2]
DR   Ensembl; ENST00000510038; ENSP00000424971; ENSG00000113648.
DR   Ensembl; ENST00000511689; ENSP00000423563; ENSG00000113648.
DR   GeneID; 9555; -.
DR   KEGG; hsa:9555; -.
DR   UCSC; uc003lam.1; human. [O75367-1]
DR   UCSC; uc003lan.1; human. [O75367-2]
DR   UCSC; uc003lao.1; human. [O75367-3]
DR   CTD; 9555; -.
DR   GeneCards; GC05M134669; -.
DR   HGNC; HGNC:4740; H2AFY.
DR   HPA; HPA041189; -.
DR   HPA; HPA050962; -.
DR   MIM; 610054; gene.
DR   neXtProt; NX_O75367; -.
DR   PharmGKB; PA29117; -.
DR   eggNOG; COG2110; -.
DR   GeneTree; ENSGT00760000119217; -.
DR   HOVERGEN; HBG009342; -.
DR   InParanoid; O75367; -.
DR   KO; K11251; -.
DR   OMA; KGGKEFT; -.
DR   OrthoDB; EOG71G9VP; -.
DR   PhylomeDB; O75367; -.
DR   TreeFam; TF332276; -.
DR   ChiTaRS; H2AFY; human.
DR   EvolutionaryTrace; O75367; -.
DR   GeneWiki; H2AFY; -.
DR   GenomeRNAi; 9555; -.
DR   NextBio; 35835; -.
DR   PMAP-CutDB; O75367; -.
DR   PRO; PR:O75367; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; O75367; -.
DR   CleanEx; HS_H2AFY; -.
DR   ExpressionAtlas; O75367; baseline and differential.
DR   Genevisible; O75367; HS.
DR   GO; GO:0001740; C:Barr body; IDA:UniProtKB.
DR   GO; GO:0000793; C:condensed chromosome; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:UniProtKB.
DR   GO; GO:0000228; C:nuclear chromosome; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000786; C:nucleosome; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005721; C:pericentric heterochromatin; IDA:BHF-UCL.
DR   GO; GO:0001739; C:sex chromatin; TAS:BHF-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0010385; F:double-stranded methylated DNA binding; IDA:UniProtKB.
DR   GO; GO:0031492; F:nucleosomal DNA binding; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; IMP:UniProtKB.
DR   GO; GO:0000182; F:rDNA binding; IDA:UniProtKB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0016568; P:chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0007549; P:dosage compensation; IDA:MGI.
DR   GO; GO:0071169; P:establishment of protein localization to chromatin; IMP:UniProtKB.
DR   GO; GO:1902750; P:negative regulation of cell cycle G2/M phase transition; IMP:UniProtKB.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IMP:UniProtKB.
DR   GO; GO:0061086; P:negative regulation of histone H3-K27 methylation; IMP:UniProtKB.
DR   GO; GO:0051572; P:negative regulation of histone H3-K4 methylation; IMP:UniProtKB.
DR   GO; GO:0033128; P:negative regulation of histone phosphorylation; IMP:UniProtKB.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:1901837; P:negative regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter; IMP:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; NAS:UniProtKB.
DR   GO; GO:0045815; P:positive regulation of gene expression, epigenetic; IMP:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0040029; P:regulation of gene expression, epigenetic; IMP:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IMP:UniProtKB.
DR   Gene3D; 1.10.20.10; -; 1.
DR   InterPro; IPR021171; Core_histone_macro-H2A.
DR   InterPro; IPR009072; Histone-fold.
DR   InterPro; IPR007125; Histone_core_D.
DR   InterPro; IPR002119; Histone_H2A.
DR   InterPro; IPR002589; Macro_dom.
DR   Pfam; PF00125; Histone; 1.
DR   Pfam; PF01661; Macro; 1.
DR   PIRSF; PIRSF037942; Core_histone_macro-H2A; 1.
DR   PRINTS; PR00620; HISTONEH2A.
DR   SMART; SM00506; A1pp; 1.
DR   SMART; SM00414; H2A; 1.
DR   SUPFAM; SSF47113; SSF47113; 1.
DR   PROSITE; PS51154; MACRO; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromatin regulator;
KW   Chromosome; Complete proteome; DNA-binding; Isopeptide bond;
KW   Methylation; Nucleosome core; Nucleus; Phosphoprotein;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN         1    372       Core histone macro-H2A.1.
FT                                /FTId=PRO_0000055318.
FT   DOMAIN        2    117       Histone H2A.
FT   DOMAIN      184    370       Macro. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00490}.
FT   COMPBIAS    118    162       Lys-rich.
FT   MOD_RES      18     18       N6-methyllysine.
FT                                {ECO:0000269|PubMed:16210244}.
FT   MOD_RES     116    116       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9QZQ8}.
FT   MOD_RES     123    123       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000305|PubMed:16210244}.
FT   MOD_RES     123    123       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9QZQ8}.
FT   MOD_RES     129    129       Phosphothreonine.
FT                                {ECO:0000269|PubMed:16210244,
FT                                ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:17924679,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     170    170       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     173    173       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     178    178       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231}.
FT   CROSSLNK    116    116       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate. {ECO:0000269|PubMed:16129414}.
FT   CROSSLNK    117    117       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16129414}.
FT   VAR_SEQ     159    159       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:12800201,
FT                                ECO:0000303|PubMed:9653160}.
FT                                /FTId=VSP_038379.
FT   VAR_SEQ     198    229       NLIHSEISNLAGFEVEAIINPTNADIDLKDDL -> QVVQA
FT                                DIASIDSDAVVHPTNTDFYIGGEV (in isoform 1).
FT                                {ECO:0000303|PubMed:9714746}.
FT                                /FTId=VSP_002056.
FT   CONFLICT    186    186       L -> F (in Ref. 3; BAB14565).
FT                                {ECO:0000305}.
FT   CONFLICT    210    210       F -> S (in Ref. 3; BAB14565).
FT                                {ECO:0000305}.
FT   CONFLICT    225    225       L -> P (in Ref. 1; AAC33433).
FT                                {ECO:0000305}.
FT   CONFLICT    291    291       E -> G (in Ref. 5; AAH95406).
FT                                {ECO:0000305}.
FT   HELIX        15     19       {ECO:0000244|PDB:2F8N}.
FT   HELIX        25     35       {ECO:0000244|PDB:2F8N}.
FT   STRAND       36     38       {ECO:0000244|PDB:2F8N}.
FT   STRAND       39     41       {ECO:0000244|PDB:1U35}.
FT   HELIX        44     70       {ECO:0000244|PDB:2F8N}.
FT   STRAND       74     76       {ECO:0000244|PDB:2F8N}.
FT   HELIX        78     86       {ECO:0000244|PDB:2F8N}.
FT   HELIX        89     94       {ECO:0000244|PDB:2F8N}.
FT   TURN         95     97       {ECO:0000244|PDB:2F8N}.
FT   STRAND       98    100       {ECO:0000244|PDB:2F8N}.
FT   HELIX       111    113       {ECO:0000244|PDB:2F8N}.
FT   STRAND      174    177       {ECO:0000244|PDB:3IVB}.
FT   STRAND      185    190       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      196    202       {ECO:0000244|PDB:1ZR3}.
FT   HELIX       204    206       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      213    219       {ECO:0000244|PDB:1ZR3}.
FT   HELIX       227    252       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      260    264       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      268    277       {ECO:0000244|PDB:1ZR3}.
FT   HELIX       286    303       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      307    311       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      315    319       {ECO:0000244|PDB:2FXK}.
FT   HELIX       323    340       {ECO:0000244|PDB:1ZR3}.
FT   STRAND      341    343       {ECO:0000244|PDB:1ZR5}.
FT   STRAND      348    355       {ECO:0000244|PDB:1ZR3}.
FT   HELIX       356    367       {ECO:0000244|PDB:1ZR3}.
SQ   SEQUENCE   372 AA;  39617 MW;  37DED989EF7E69DC CRC64;
     MSSRGGKKKS TKTSRSAKAG VIFPVGRMLR YIKKGHPKYR IGVGAPVYMA AVLEYLTAEI
     LELAGNAARD NKKGRVTPRH ILLAVANDEE LNQLLKGVTI ASGGVLPNIH PELLAKKRGS
     KGKLEAIITP PPAKKAKSPS QKKPVSKKAG GKKGARKSKK KQGEVSKAAS ADSTTEGTPA
     DGFTVLSTKS LFLGQKLNLI HSEISNLAGF EVEAIINPTN ADIDLKDDLG NTLEKKGGKE
     FVEAVLELRK KNGPLEVAGA AVSAGHGLPA KFVIHCNSPV WGADKCEELL EKTVKNCLAL
     ADDKKLKSIA FPSIGSGRNG FPKQTAAQLI LKAISSYFVS TMSSSIKTVY FVLFDSESIG
     IYVQEMAKLD AN
//
